Kotyark Industries Limited reports H2 & FY22 results3 min read
Vadodara (Gujarat) [India], May 14: Kotyark Industries Limited, India’s only pure play listed Biodiesel Company, has announced its financial results for the half-year and year ended March 31st, 2022. The company announced an increase of 727 % in profit and declares dividend of ₹ 2.
Financial Highlights for the half-year ended March 31st, 2022:
- Revenue from Operations stood at ₹ 8,974.83 Lakhs in H2FY22 compared to ₹ 3,470.91 Lakhs in H2FY21 and ₹ 6,629.76 Lakhs in H1FY22, an increase of 159% YoY and 35% sequentially
- EBITDA (excluding Other Income) stood at ₹04 Lakhs in H2FY22, an increase of 450% YoY and 202% sequentially
- EBITDA margins stood at 7% in H2FY22, an increase of 565 bps YoY and 588 bps sequentially
- PAT stood at ₹65 Lakhs in H2FY22 compared to ₹ 72.82 Lakhs in H2FY21 and ₹ 197.37 Lakhs in H1FY22, an increase of 815% YoY and 238% sequentially
Financial Highlights for the year ended March 31st, 2022 :
- Revenue from Operations stood at ₹ 15,604.59 Lakhs in FY22 compared to ₹ 6,520.61 Lakhs in FY21, an increase of 139% YoY
- EBITDA (excluding Other Income) stood at ₹ 1,272.32 Lakhs in FY22, an increase of 338% YoY
- EBITDA margins stood at 2% in FY22, an increase of 370 bps YoY
- PAT stood at ₹04 Lakhs in FY22 compared to ₹ 104.44 Lakhs in FY21, an increase of 727% YoY
Commenting on the H2 & FY22 performance, Gaurang Shah, Chairman and Managing Director, said:
“Your Company has reported robust numbers in its H2 & FY22 results. I am pleased to state that we have set a new benchmark for ourselves in terms of topline, operating profits and bottom line. Our FY22 Revenue from Operations stood at an all-time high of ₹156.05 crores, an increase of 139% on a Y-o-Y basis. This growth has been despite a delayed rise in fuel prices in Q4FY22. The Company has been driving growth primarily on the basis of higher volumes and better utilisation of its manufacturing facility. As a result, Operating Profit margins for the year FY22 stood significantly higher at 8.2% compared to 4.5% in the previous year. An increase in margins coupled with a significant increase in topline led to an exponential 727% increase in net profit for the year under review.
On the operational front, Kotyark Industries has added 8 more mobile retail outlets (MRO) of biodiesel under its brand ‘Green N Green’, which puts the total to 25 such operational MRO’s. Further, in line with its strategy of expanding Retail Outlets’ revenue stream, the Company plans to apply for 50 more licenses. The Company has also made noteworthy progress in leveraging the benefits of carbon credits in its business. At present, the Company is envisaging a potential ~4 lakh units of carbon credit, given its current scale of operations. We have also recommended a dividend of Rs 2 per share to our shareholders, subject to approval at the AGM, in light of our robust financial performance and strengthened balance sheet position.
As we set out to revolutionise the fuel industry by enabling sustainable alternative energy, we are pleased with the direction that the Indian government has accorded. We are confident that policy changes such as the envisaged 5% blending targets of biodiesel in diesel by 2030 will augment our performance in the coming years and will enable us to realise our goal of becoming the leading biodiesel manufacturer in India. Furthermore, our performance for the year adds legitimacy to our goals, and we are confident that we will be able to deliver on our promises.”
Kotyark Industries Limited, incorporated in 2016, is engaged in the manufacturing of biodiesel and its by-products, and is one of the key players across the state of Rajasthan in India. The Company focuses on green energy and sustainable development of renewable resources (biofuel) through the adoption of environmentally friendly technology. It’s manufacturing unit at Swaroopganj, District Sirohi, RICCO, Rajasthan has a capacity of producing 500 KL of biodiesel per day from multi feedstock.
15 thoughts on “Kotyark Industries Limited reports H2 & FY22 results”
buying cialis online forum Then it s highly likely you have adrenal fatigue
comprar cialis online E 4 1 4 2 Dimethylamino ethoxy phenyl 2 phenyl 1 buten 1 yl phenol 1 acetate; CAS 76117 70 9;
875 USD420m 2022s in full, as well as USD700m of 7 USD850m 2020 senior notes at 101 plus accrued and unpaidinterest where to buy priligy in malaysia Total of two patients 22
propecia prescription What I love about it too is that it is versatile; for as many ways there are to spell it, there are just as many ways to make it
buy real cialis online At this moment, Lei Cheng was holding this sword, and in his eyes, he looked at Huang Qing with a little confidence, and said lightly This sword is called Linglei Sword
Accordingly, strictures including inflammatory alterations might benefit from anti inflammatory therapy through a reduction of the inflammation mediated edema 5 does cvs sell viagra 4 OTC Hydrocodone e
buy cialis professional Next, we analyzed serial surface ECGs of patients who received cardiac RT
best site to buy cialis online The family should be advised not to make inappropriate or offensive comments in the presence of the patient
Kilic- Okman, T buy priligy generic fig 8b flow cytometry; human; 1 800; fig s1 western blot; human; 1 500; loading
propecia and rogaine As I recall, they also didn t excrete quite as much we measured urinary excretion down to the milliliter and graphed it over the four hours
Taking panax ginseng along with diabetes medications might cause blood sugar to drop too low priligy
discreet cialis meds Whether you are young or past menopause, single or in a long term relationship, it is never too late or too early to realize YOU ARE NOT BROKEN
Email for general inquiries info commonsnews cialis generic reviews
Klf4 has been shown to be undetectable within large conduit arteries at baseline but is rapidly upregulated upon vascular injury 26, 43 cheap cialis online
For the assessment of capillary formation, endothelial cells were harvested, and 1 can you buy cialis online ciprofloxacin 500 mg x 2 I andra hand